Atrion (NASDAQ:ATRI) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Atrion (NASDAQ:ATRI) from a hold rating to a sell rating in a research note published on Monday morning.

Atrion Trading Down 0.6 %

Shares of Atrion stock opened at $399.83 on Monday. The firm has a market capitalization of $703.70 million, a PE ratio of 36.25 and a beta of 0.60. The firm’s 50 day moving average is $401.31 and its 200 day moving average is $364.59. Atrion has a 1 year low of $274.98 and a 1 year high of $643.48.

Atrion (NASDAQ:ATRI) last posted its earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share for the quarter. The firm had revenue of $43.58 million for the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%.

Atrion Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 15th were given a dividend of $2.20 per share. The ex-dividend date was Thursday, March 14th. This represents a $8.80 dividend on an annualized basis and a dividend yield of 2.20%. Atrion’s payout ratio is presently 79.78%.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ATRI. Copeland Capital Management LLC lifted its position in shares of Atrion by 56.4% during the 4th quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock valued at $33,000 after acquiring an additional 31 shares during the period. Quadrant Capital Group LLC acquired a new position in Atrion during the fourth quarter worth $36,000. Harbor Investment Advisory LLC raised its holdings in Atrion by 33.1% during the fourth quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier’s stock worth $72,000 after buying an additional 47 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Atrion by 592.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock worth $102,000 after buying an additional 231 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in Atrion during the fourth quarter worth $108,000. Institutional investors and hedge funds own 66.19% of the company’s stock.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.